Core Insights - Immuneering Corporation reported positive data from its ongoing Phase 2a trial of IMM-1-104, showing an overall response rate (ORR) of 43% and a disease control rate (DCR) of 86% in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer [3][4] - The company has entered a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo for non-small cell lung cancer [4][8] - Cash runway has been extended into 2026, providing sufficient funding for ongoing operations [9] Clinical Developments - The Phase 2a trial of IMM-1-104 demonstrated promising results, with an ORR of 50% when combined with modified FOLFIRINOX, compared to historical benchmarks of 23% and 32% for the respective chemotherapy agents [3][4] - Plans are underway for a potential global pivotal trial of IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel [3][4] - Additional combination arms for IMM-1-104 are expected to be initiated in 2025, including studies with a BRAF inhibitor, a G12C inhibitor, and a PD-1 inhibitor [4][8] Financial Performance - As of December 31, 2024, the company reported cash and cash equivalents of $36.1 million, a decrease from $85.7 million as of December 31, 2023 [7][19] - Research and development (R&D) expenses for Q4 2024 were $14.9 million, up from $11.9 million in Q4 2023, reflecting increased clinical costs related to IMM-1-104 [7][17] - The net loss for Q4 2024 was $18.1 million, or $0.58 per share, compared to a net loss of $15.1 million, or $0.52 per share, for Q4 2023 [7][17] Leadership Changes - Dr. Igor Matushansky has been appointed as Chief Medical Officer to oversee clinical activities and development programs [4][5]

Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of IMM-1-104 in pancreatic cancer in Q2 2025 CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Immuneering (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that Igor Matushans ...

- Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase 2a trial – - Data presented at AACR 2023 supports dual-targeting potential of IMM-1-104 in combination with anti-PD-1 – CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) --  Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced a ...

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief E ...

- Two new partial responses (PRs) reported in Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer - - Overall Response Rate (ORR) of 50%; historic benchmark of 32% for FOLFIRINOX alone - - Nearly $14M in net proceeds raised in January 2025 through utilization of Company's ATM - CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effecti ...

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response rate (ORR = 43%) and disease control rate (DCR = 86%); planning for pivotal trial underway - - Favorable initial data for IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer patients show target lesion shrinkage in all evaluable patients, including a 100% reduction (PR) - - Encouraging initial data for IMM-1- ...

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 - CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation ...

- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and ...

- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors - - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma patients actively enrolling in one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinica ...

CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Palace in New York City from December 3-5, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating wil ...